GLY-200

GLY-200 is an experimental drug that acts as a "polymeric mucin binding duodenal exclusion therapy"; it is developed by Glyscend Therapeutics for type 2 diabetes and obesity. It is intended to reversibly mimic the effects of gastric bypass without the need for surgery. The drug is not absorbed into the body from the gut and has been tested as monotherapy and with metformin.^[1]^[2]^[3]^[4]^[5]^[6]

References

^ Significant Weight Loss Due to a Novel Oral Polymeric Mucin Binding Duodenal Exclusion Therapy Nimgaonkar, Ashish, MD; Sanglard, Larissa, MD; Habegger, Kirk, PhD; Colbert, Kevin, MS; Carlson, Taylor, PhD; et al. Obesity; Silver Spring Vol. 29, (Dec 2021): 162.
^ A First-in-Human Study of GLY-200, an Oral, Gut- Restricted, Pharmacologic Duodenal Exclusion Therapy Fineman, Mark, PhD; Bryant, Christine, PhD; Colbert, Kevin, MS; Jozefiak, Thomas, PhD; Petersen, John, PhD; et al. Obesity; Silver Spring Vol. 30, (Nov 2022): 19.
^ Fineman, Mark S.; Bryant, Christine L. N.; Colbert, Kevin; Jozefiak, Thomas H.; Petersen, John S.; Horowitz, Michael; Vora, Jiten; Rayner, Christopher K.; Wabnitz, Paul; Nimgaonkar, Ashish (September 2023). "First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations". Diabetes, Obesity and Metabolism. 25 (9): 2447–2456. doi:10.1111/dom.15066. PMID 37380614.
^ Fick, Maggie (7 July 2023). "Biotech firms target weight-loss drugs without Wegovy's side-effects". Reuters. Retrieved 5 December 2023.
^ Fineman, Mark; Bryant, Christine; Jozefiak, Thomas H.; Nimgaonkar, Ashish; Carlson, Taylor (20 June 2023). "832-P: Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat". Diabetes. 72 (Supplement_1). doi:10.2337/db23-832-P. S2CID 259395861.
^ Nimgaonkar, Ashish; Bryant, Christine; Habegger, Kirk M.; Colbert, Kevin; Carlson, Taylor; Polomoscanik, Steven; Petersen, John S.; Jozefiak, Thomas H.; Fineman, Mark (20 June 2023). "823-P: GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat". Diabetes. 72 (Supplement_1). doi:10.2337/db23-823-P. S2CID 259423112.

[1] Significant Weight Loss Due to a Novel Oral Polymeric Mucin Binding Duodenal Exclusion Therapy Nimgaonkar, Ashish, MD; Sanglard, Larissa, MD; Habegger, Kirk, PhD; Colbert, Kevin, MS; Carlson, Taylor, PhD; et al. Obesity; Silver Spring Vol. 29, (Dec 2021): 162.

[2] A First-in-Human Study of GLY-200, an Oral, Gut- Restricted, Pharmacologic Duodenal Exclusion Therapy Fineman, Mark, PhD; Bryant, Christine, PhD; Colbert, Kevin, MS; Jozefiak, Thomas, PhD; Petersen, John, PhD; et al. Obesity; Silver Spring Vol. 30, (Nov 2022): 19.

[3] Fineman, Mark S.; Bryant, Christine L. N.; Colbert, Kevin; Jozefiak, Thomas H.; Petersen, John S.; Horowitz, Michael; Vora, Jiten; Rayner, Christopher K.; Wabnitz, Paul; Nimgaonkar, Ashish (September 2023). "First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations". Diabetes, Obesity and Metabolism. 25 (9): 2447–2456. doi:10.1111/dom.15066. PMID 37380614.

[4] Fick, Maggie (7 July 2023). "Biotech firms target weight-loss drugs without Wegovy's side-effects". Reuters. Retrieved 5 December 2023.

[5] Fineman, Mark; Bryant, Christine; Jozefiak, Thomas H.; Nimgaonkar, Ashish; Carlson, Taylor (20 June 2023). "832-P: Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat". Diabetes. 72 (Supplement_1). doi:10.2337/db23-832-P. S2CID 259395861.

[6] Nimgaonkar, Ashish; Bryant, Christine; Habegger, Kirk M.; Colbert, Kevin; Carlson, Taylor; Polomoscanik, Steven; Petersen, John S.; Jozefiak, Thomas H.; Fineman, Mark (20 June 2023). "823-P: GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat". Diabetes. 72 (Supplement_1). doi:10.2337/db23-823-P. S2CID 259423112.

[1]

[2]

[3]

[4]

[5]

[6]